BRAF and cancer: Low AREG and EREG mRNA levels in mCRC tumor tissues are associated with BRAF mutations and correlated with shorter OS in patients with cancer-receiving oxaliplatin/fluoropyrimidine and bevacizumab as combinational treatment [69].